

Claim 1, wherein the agonist is selected from the group consisting of sulprostone, compound TEI3356, compound M&B-28767, and prostaglandin PGE1.

3. (Previously amended) The method according to Claim 1, wherein the agonist is applied in a composition suitable for topical administration.

4. (Previously amended) The method according to Claim 3, wherein the composition comprises from 0.001% to 10% of the agonist by weight relative to the weight of the composition.

5. (Previously amended) The method according to Claim 3, wherein the cosmetic composition further comprises a prostaglandin EP-2 receptor antagonist, a prostaglandin EP-4 receptor antagonist, or a combination thereof.

6. (Currently amended) The method according to Claim 3, wherein the composition further comprises a cosmetically acceptable medium including water or mixture of water and at least one organic solvent selected from the group consisting of hydrophilic organic solvents, lipophilic organic solvents, amphiphilic solvents, and mixtures thereof.

7. (Previously amended) The method according to Claim 6, wherein the organic solvent is selected from the group consisting of monofunctional or polyfunctional alcohols,

oxyethylenated polyethylene glycols, polypropylene glycol esters, sorbitol and derivatives thereof, dialkyl isosorbides, glycol ethers, polypropylene glycol ethers, and fatty esters.

8. (Previously amended) The method according to Claim 6, wherein the organic solvent is present in an amount of 5% to 98% of the total weight of the composition.

9. (Previously amended) The method according to Claim 3, wherein the composition further comprises at least one fatty phase.

10. (Previously amended) The method according to Claim 9, wherein the fatty phase is present in an amount of 50% or less of the total weight of the composition.

11. (Previously amended) The method according to Claim 3, wherein the composition further comprises at least one additive selected from the group consisting of: conventional hydrophilic or lipophilic gelling agents; conventional hydrophilic or lipophilic thickeners; hydrophilic or lipophilic active agents; preserving agents; antioxidants; fragrances; emulsifiers; moisturizers; pigmenting agents; depigmenting agents; keratolytic agents; vitamins; emollients; sequestering agents; surfactants; polymers; acidifying or basifying agents; fillers; free-radical scavengers; ceramides; sunscreens; insect

repellents; slimming agents; colorants; bactericides; and anti-dandruff agents.

12. (Currently amended) The method according to Claim 3, wherein the composition is an aqueous solution, an aqueous-alcoholic solution, an oily solution, an oil-in-water emulsion, a water-in-oil emulsion, a multiple emulsion, an aqueous gel, an oily gel, a liquid anhydrous product, a pasty anhydrous product, a solid anhydrous product, or a dispersion of oil in an aqueous phase with the aid of spherules.

01
13. (Previously amended) The method according to Claim 3, wherein the composition has an appearance of a white cream, a colored cream, an ointment; a milk, a lotion, a serum, a paste, a mousse, or a solid.

14. (Previously amended) The method according to Claim 3, wherein the composition has a pH of between 3 and 8.

15. (Previously amended) A cosmetic treatment process for attenuating, reducing or stopping the growth of hair which comprises applying to the hair a cosmetically effective amount of the agonist of Claim 1.

16. (Previously amended) A cosmetic treatment process for attenuating, reducing or stopping the growth of hair which comprises applying to the hair and the composition of Claim 3.

17. (Original) The method according to Claim 1,
wherein the hair is head hair.

18. (Original) The method according to Claim 3,
wherein the composition comprises from 0.1% to 5% of the agonist
by weight relative to the weight of the composition.

Original
19. (Original) The process according to Claim 15,
wherein the hair is head hair.

20. (Original) The process according to Claim 16,
wherein the hair is head hair.
